An international study led by scientists at St. Jude Children’s Research Hospital provides one reason for the low survival rates for adults with acute lymphoblastic leukemia (ALL). Researchers showed that nearly a quarter of adult ALL cases have a high-risk subtype called Ph-like ALL. The five-year survival rate for these patients was almost 25 percent. Researchers found evidence that adults with Ph-like ALL may benefit drugs like ruxolitinib, imatinib and dasatinib. These drugs are already used to treat other types of leukemia and work by inhibiting the activity of specific enzymes known as tyrosine kinases. Clinical trials are needed to determine if the drugs could improve patient outcomes.

Journal of Clinical Oncology paper: [ Ссылка ]
Study Press Release: [ Ссылка ]
Charles Mullighan | Pathology Department: [ Ссылка ]

свернуть